Evidence map›Paper›PMID 41774768›Full record

ArticlePLoS pathogens2026

Duration of immunity following infection with moderately virulent ASFV.

Virginia Friedrichs, Paul Deutschmann, Kerstin Wernike, Tessa Carrau, Martin Beer, Sandra Blome, Alexander Schäfer

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Virginia FriedrichsFriedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald Insel-Riems, Germany.
Paul DeutschmannFriedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald Insel-Riems, Germany.
Kerstin WernikeFriedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald Insel-Riems, Germany.
Tessa CarrauDepartment of Virology and Serology, Landesuntersuchungsanstalt für das Gesundheits- und Veterinärwesen Sachsen, Dresden, Germany.
Martin BeerFriedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald Insel-Riems, Germany.
Sandra BlomeFriedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald Insel-Riems, Germany.ORCID https://orcid.org/0000-0001-5465-5609
Alexander SchäferFriedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald Insel-Riems, Germany.ORCID https://orcid.org/0000-0002-4258-0651

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

African swine fever virus (ASFV) poses a significant threat to pork production and wild pig populations worldwide. The study assessed the long-term fate and immunity of animals recovering from a moderately virulent ASFV infection, following the principles of a duration of immunity study for live vaccines. Pigs inoculated with the moderately virulent ASFV strain Estonia14 largely developed mild clinical signs and only transient viremia. Six months after the initial inoculation and once fully recovered, all the animals were challenged with highly virulent ASFV Armenia08. Only one of the previously exposed pigs exhibited mild clinical signs, while all control animals showed typical signs of acute, lethal ASF. Moreover, only a subset of pigs inoculated with the ASF strain Estonia14 displayed temporary detectability of ASFV genomes following challenge infection. Virus isolation corroborated these findings, with low levels of infectious virus in organs of previously inoculated pigs (28 days post challenge). Furthermore, monitoring of ASFV-specific IgM and IgG kinetics enabled the analysis of humoral responses. IgG levels were sustained over the study period and increased slightly upon challenge infection. Lastly, plasma analysis revealed elevated complement factor C3a levels post inoculation and challenge in the recovered pigs, directly correlating with challenge virus presence. In contrast, both C3a and C5a levels were increased in the control group. It could be shown that complement system activation was mediated by the lectin pathway, possibly by interaction of mannose-binding lectins and ASFV particles. This study suggests that protective immunity following recovery can last at least six months. No cases of persistent or chronic disease were observed in convalescent pigs. These findings have implications for both vaccine development and assessment, as well as for disease control strategies including surveillance actions.

Indexed as

African Swine FeverAfrican Swine Fever VirusAnimalsAntibodies, ViralImmunoglobulin GImmunoglobulin MSwineViremiaVirulenceAntibodies, ViralImmunoglobulin GImmunoglobulin M

Identifiers

PMID41774768
PMCPMC12970971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.